Patents Assigned to Janssen Pharmaceutica
  • Patent number: 11618744
    Abstract: The present invention is directed to benzoimidazole compounds of the formula: and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: April 4, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Frances Meredith Hocutt, Barry Eastman Leonard, Jr., Hillary M. Peltier, Victor K. Phuong, Michael H. Rabinowitz, Mark D. Rosen, Kyle T. Tarantino, Hariharan Venkatesan, Lucy Xiumin Zhao
  • Patent number: 11618750
    Abstract: Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: April 4, 2023
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Afton Hiscox, Akinola Soyode-Johnson, Brice Stenne, Christa Chrovian, Christine Gelin, Andrew Samant, Michael A. Letavic, Curt Dvorak
  • Publication number: 20230099293
    Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.
    Type: Application
    Filed: December 18, 2020
    Publication date: March 30, 2023
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: José Manuel BARTOLOMÉ-NEBREDA, Petrus Jacobus Johannes Antonius BUIJNSTERS, Ana Isabel DE LUCAS OLIVARES, Joseph Elisabeth LEENAERTS, Carolina MARTINEZ LAMENCA, Daniel OEHLRICH, Andrés Avelino TRABANCO-SUÁREZ, Yves Emiel M VAN ROOSBROECK, Adriana Ingrid VELTER
  • Patent number: 11615288
    Abstract: The present disclosure relates to secure broker-mediated data analysis and prediction. One example embodiment includes a method. The method includes receiving, by a managing computing device, a plurality of datasets from client computing devices. The method also includes computing, by the managing computing device, a shared representation based on a shared function having one or more shared parameters. Further, the method includes transmitting, by the managing computing device, the shared representation and other data to the client computing devices. In addition, the method includes, based on the shared representation and the other data, the client computing devices update partial representations and individual functions with one or more individual parameters. Still further, the method includes determining, by the client computing devices, feedback values to provide to the managing computing device.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: March 28, 2023
    Assignees: IMEC VZW, JANSSEN PHARMACEUTICA NV, KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventors: Hugo Ceulemans, Roel Wuyts, Wilfried Verachtert, Jaak Simm, Adam Arany, Yves Moreau, Charlotte Herzeel
  • Patent number: 11615713
    Abstract: Cognitive and mood states of a real world person are assessed according to activity in a virtual world environment with which the person interacts. The virtual world is configured to provide interactive experiences for assessing the person's cognitive and/or mood states. The system requires configuration of a session avatar during each virtual world session to provide then-current insight into the person's mood state. The system may require configuration of an avatar reflective of the person's state. The system requires the person to configure the virtual world environment during each virtual session to provide then-current insight into the person's mood state. The system permits the user to visit destinations, perform tasks and play games that are included in the environment for the purpose of providing insight into the person's cognitive and/or mood states according to the person's selections and/or performance.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: March 28, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Joseph Barbuto, Katherine Bettencourt, Carine Brouillon, Gabriel Brun, Alexandra Kramer, Joe Manfredonia, Husseini Manji, Kenneth Mosca, Mark Sapp, Magdalena Schoeneich
  • Patent number: 11597728
    Abstract: Bridged compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein R2, R3 R4, R5 and R6 are defined herein.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: March 7, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Michael K. Ameriks, Gang Chen, Chaofeng Huang, Brian Ngo Laforteza, Suchitra Ravula, Wei Zhang
  • Patent number: 11590155
    Abstract: Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: February 28, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Lawrence M. Blatt, Leonid Beigelman, Natalia Dyatkina, Julian Alexander Symons, David Bernard Smith
  • Patent number: 11591379
    Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: February 28, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Yue-Mei Zhang, Mark J. Wall, Ellen Chi
  • Publication number: 20230058733
    Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations; or alpha synucleinopathies, in particular Parkinson's disease, dementia due to Parkinson's (or neurocognitive disorder due to Parkinson's disease), dementia with Lewy bodies, multiple system atrophy, or alpha synucleinopathy caused by Gaucher's disease.
    Type: Application
    Filed: December 18, 2020
    Publication date: February 23, 2023
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: José Manuel BARTOLOMÉ-NEBREDA, Petrus Jacobus Johannes Antonius BUIJNSTERS, Joseph Elisabeth LEENAERTS, Carolina MARTINEZ LAMENCA, Daniel OEHLRICH, Andrés Avelino TRABANCO-SUÁREZ, Yves Emiel M VAN ROOSBROECK, Adriana Ingrid VELTER
  • Patent number: 11583524
    Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds: wherein n, m, p, s, t, R1, R2, R3, R4, R5, R6, R7, R20, X, Y, Q and Z have defined meanings.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: February 21, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Virginie Sophie Poncelet, Sophie Coupa, Pierre-Henri Storck, Bruno Schoentjes
  • Publication number: 20230045960
    Abstract: Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Application
    Filed: September 12, 2022
    Publication date: February 16, 2023
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Afton HISCOX, Brice STENNE, Christa CHROVIAN, Christine GELIN, Andrew SAMANT, Michael A. LETAVIC, Curt DVORAK
  • Patent number: 11576894
    Abstract: The present invention is directed to co-therapy and methods for the treatment and prevention of glucose-related disorders such as Type 2 diabetes mellitus and Syndrome X. The present invention is further directed to pharmaceutical compositions for the co-therapy and methods described herein.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: February 14, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Yin Liang, John Ryan, Abraham B. Woldu, Lisa Wu
  • Patent number: 11571437
    Abstract: The present disclosure provides methods for treating a human patient diagnosed with a cancer, comprising administering a therapeutically effective amount of a PRMT5 (protein arginine methyltransferase 5) inhibitor, certain methods comprising (i) administering to the patient initial doses of at least about 0.1 mg per day of the PRMT5 inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharmaceutically acceptable addition salt or solvate thereof for an initial dosing period of about 5 to about 21 days; and (ii) administering to the patient subsequent doses of at least about 0.1 mg per day of the PRMT5 inhibitor for one or more subsequent dosing periods of about 5 to about 21 days each. In these methods, a first subsequent dosing period is separated in time from the initial dosing period by at least about 5 days and the subsequent dosing periods are separated in time from each other by at least about 5 days.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: February 7, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Hillary Joy Millar Quinn, Kathryn Elizabeth Packman, Nahor Haddish-Berhane, Geert S. J. Mannens, Junguo Zhou, Anthony T. Greway, Dirk Brehmer, Yue Guo, Tongfei Wu, Hong Xie, Josh Lauring
  • Patent number: 11574562
    Abstract: A device for training users in a proper mixing of pharmaceutical components, or for aiding in the mixing, or for performing the mixing, and administration of pharmaceutical components is disclosed. The device comprises a housing for receiving a pharmaceutical delivery device containing the pharmaceutical components. There is also a microcontroller disposed in the housing and a motion/orientation detection device disposed within or on the housing and in communication with the microcontroller. A method for use of the device is also disclosed, along with a substance for use as one of the pharmaceutical components.
    Type: Grant
    Filed: October 27, 2020
    Date of Patent: February 7, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Peter A. Krulevitch, Ian Scrimgeour, Scott Martin, James McLusky, James Glencross, Blair Hutton, Nick Foley, Jose Antonio Buron Vidal
  • Patent number: 11559540
    Abstract: The disclosed method rapidly identifies with desired accuracy AML patients, including elderly AML patients, likely to respond to treatment with a combination of a farnesyltransferase inhibitor and one or more of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan, trastuzumab and cisplatinum. In an embodiment, the improvements include the use of whole blood rather than the customary bone marrow sample, thus making the assay more accurate, rapid, less intrusive, less expensive as well as less painful. The method includes evaluation of a two-gene expression ratio (RASGRP1:APTX), which with a corresponding threshold, provides sufficient accuracy for predicting the response to the combination treatment. In the preferred embodiment the combination treatment combines tipifarnib (R115777, ZARNESTRA®) with etoposide.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: January 24, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tatiana I. Vener, Carlo C. Derecho, John F. Palma, Mical Raponi
  • Publication number: 20230000833
    Abstract: Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Application
    Filed: September 14, 2021
    Publication date: January 5, 2023
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Christa C. Chrovian, Michael A. Letavic, Jason C. Rech, Dale A. Rudolph, Akinola Soyode-Johnson, Brice M. Stenne, Jessica L. Wall
  • Patent number: 11542247
    Abstract: The invention relates to new quinoline, pyridopyrazine, naphthyridine and quinazolinone derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: January 3, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Rene Angibaud, Diego Fernando Domenico Broggini, Filip Albert C Cuyckens, Steven Anna Hostyn, Russell Mark Jones, Olivier Alexis Georges Querolle, Wim Vermeulen
  • Patent number: 11539506
    Abstract: Embodiments facilitate interoperability and secure determination of healthcare costs. An entity may receive a first Electronic Health Record (EHR) sub-block with patient medical coverage information and first treatments and may transmit a first Device Drug Information (DIR) sub-block comprising first treatment classes corresponding to each first treatment, first treatment class members corresponding to each first treatment class, and corresponding first treatment class member cost information. In response, the entity may receive a second EHR sub-block comprising second treatments each: associated with a corresponding first treatment, and selected from corresponding first treatment class members. Upon receipt of a transaction confirmation, the entity may augment a multi-dimensional blockchain with a multi-dimensional block formed by linking: a DIR block including second treatment information, an EHR block including information based on the second EHR sub-block and a transaction block.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: December 27, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Jessica Lee, Jun Morimura, Michael Moschetti, John Vig, Marvin Quesada
  • Patent number: 11530226
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to azepane compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: December 20, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Rene Angibaud, Vineet Pande, Barbara Herkert, Daniel Jason Krosky, Olivier Alexis Georges Querolle, Aaron Nathaniel Patrick, Isabelle Noelle Constance Pilatte
  • Patent number: 11532385
    Abstract: Embodiments facilitate interoperability and secure patient selection for clinical trials and drug/device deployments. An entity may obtain a first set of health parameters and collective demographic information associated with one or more population segments and receive Electronic Health Record (EHR) sub-blocks with patient profile information and corresponding patient medical histories for patients. The entity may determine a subset of eligible candidate patients for a treatment based on information in the EHR sub-blocks and eligibility criteria for the treatment, which may be based the first set of health parameters, and/or the collective demographic information.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: December 20, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Jessica Lee, Jun Morimura, Michael Moschetti, John Vig, Marvin Quesada